Solid Biosciences Inc. SLDB Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Solid Biosciences Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Solid Biosciences Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Solid Biosciences Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Solid Biosciences Inc.'s additional paid-in capital?
- Solid Biosciences Inc. (SLDB) reported additional paid-in capital of $1.39B in Q1 2026.
- How has Solid Biosciences Inc.'s additional paid-in capital changed year-over-year?
- Solid Biosciences Inc.'s additional paid-in capital increased by 24.3% year-over-year, from $1.12B to $1.39B.
- What is the long-term trend for Solid Biosciences Inc.'s additional paid-in capital?
- Over 5 years (2020 to 2025), Solid Biosciences Inc.'s additional paid-in capital has grown at a 16.2% compound annual growth rate (CAGR), from $536.57M to $1.14B.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.